Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia

BACKGROUND: Apixaban, an oral anticoagulant for stroke and systemic embolism prevention in non-valvular atrial fibrillation (NVAF), was superior to warfarin in prevention of stroke and systemic embolism, bleeding outcomes and mortality (ARISTOTLE trial), and substantially reduced stroke risk, with n...

Descripción completa

Detalles Bibliográficos
Autores principales: Hersi, Ahmad S., Osenenko, Katherine M., Kherraf, Sid Ahmed, Aziz, Ayman Abdel, Sambrook, Robert Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: King Faisal Specialist Hospital and Research Centre 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838647/
https://www.ncbi.nlm.nih.gov/pubmed/31381381
http://dx.doi.org/10.5144/0256-4947.2019.265

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838647/
https://www.ncbi.nlm.nih.gov/pubmed/31381381
http://dx.doi.org/10.5144/0256-4947.2019.265

Ejemplares similares